𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Hepatitis B virus resistance to entecavir in nucleoside naïve patients: Does it exist?

✍ Scribed by Fabien Zoulim

Publisher
John Wiley and Sons
Year
2006
Tongue
English
Weight
60 KB
Volume
44
Category
Article
ISSN
0270-9139

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Entecavir resistance is rare in nucleosi
Entecavir resistance is rare in nucleoside naïve patients with hepatitis B
✍ Richard J. Colonno; Ronald Rose; Carl J. Baldick; Steven Levine; Kevin Pokornows 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 378 KB

a HBV DNA Ͻ7 ϫ 10 5 copies/mL by bDNA assay ϩ loss of HBeAg (Study AI463022) or normalization of ALT (Study AI463027). b HBV DNA Ͻ7 ϫ 10 5 copies/mL by bDNA assay. c HBV DNA Ն7 ϫ 10 5 copies/mL by bDNA assay.

Correlation of serum hepatitis B surface
Correlation of serum hepatitis B surface antigen level with response to entecavir in naïve patients with chronic hepatitis B
✍ Myoung Hee Lee; Da Mi Lee; Soon Sun Kim; Jae Youn Cheong; Sung Won Cho 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 117 KB 👁 2 views

## Abstract Recent studies have suggested that quantifying the serum HBsAg levels can predict the response to pegylated interferon. We aimed to determine the change in serum HBsAg levels during entecavir (ETV) treatment and the correlation with treatment response in chronic HBeAg‐positive and HBeAg

Naturally occurring dominant resistance
Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients
✍ Thomas Kuntzen; Joerg Timm; Andrew Berical; Niall Lennon; Aaron M. Berlin; Sarah 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 263 KB

Resistance mutations to hepatitis C virus (HCV) nonstructural protein 3 (NS3) protease inhibitors in <1% of the viral quasispecies may still allow >1000-fold viral load reductions upon treatment, consistent with their reported reduced replicative fitness in vitro. Recently, however, an R155K proteas

Long-term incidence of hepatitis B virus
Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus–infected patients
✍ Yves Benhamou; Marie Bochet; Vincent Thibault; Vincent Di Martino; Eric Caumes; 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 82 KB 👁 2 views

Hepatitis B virus (HBV) resistance to lamivudine has not been extensively documented in human immunodeficiency virus (HIV)-infected patients. We studied the long-term incidence of HBV resistance to lamivudine in HIV-positive patients. Sixty-six HIV-HBV-coinfected patients were studied while receivin

Mutations associated with lamivudine-res
Mutations associated with lamivudine-resistance in therapy-naïve hepatitis B virus (HBV) infected patients with and without HIV co-infection: Implications for antiretroviral therapy in HBV and HIV co-infected South African patients
✍ S. Gloria Selabe; Azwidowi Lukhwareni; Ernest Song; Yeegan G.M. Leeuw; Rosemary 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 97 KB 👁 1 views

## Abstract This was an exploratory study to investigate lamivudine‐resistant hepatitis B virus (HBV) strains in selected lamivudine‐naïve HBV carriers with and without human immunodeficiency virus (HIV) co‐infection in South African patients. Thirty‐five lamivudine‐naïve HBV infected patients with

Novel patterns of amino acid mutations i
Novel patterns of amino acid mutations in the hepatitis B virus polymerase in association with resistance to lamivudine therapy in Japanese patients with chronic hepatitis B
✍ Ogata, Norio; Fujii, Kyuichi; Takigawa, Shingo; Nomoto, Minoru; Ichida, Takafumi 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 160 KB 👁 2 views

Lamivudine is effective in suppressing replication of hepatitis B virus (HBV). However, the emergence of HBV variants resistant to lamivudine is a concern. Lamivudine resistance has been attributed mainly to a substitution of isoleucine or valine for methionine at residue 550 (M550I or M550V) in the